<div class="headers"><div>Figure 1. Results of the saxagliptin add-on to insulin ± metformin trial. (A) Adjusted mean changes from baseline HbA1c level (LOCF) at week 52. (B) Adjusted mean changes from baseline FPG (LOCF) at week 52. (C) Proportions of patients achieving HbA1c level  7% (LOCF) at week 52. (D) Adjusted mean changes from baseline in body weight (LOCF) at week 52 in patients with CVD history versus no CVD history, with  2 and  1 CV risk factor, with and without hypertension, and with and without statin use.Abbreviations: CV, cardiovascular; CVD, cardiovascular disease; GLIP, glipizide; HbA1c, glycated hemoglobin; MET, metformin; SAXA, saxagliptin; SE, standard error.</div></div><table class='gmisc_table' style='border-collapse: collapse; margin-top: 1em; margin-bottom: 1em;' >
<tbody>
<tr style='border-top: 2px solid grey;'>
<td style='border-top: 2px solid grey; text-align: left;'><p class="">Figure 1. Results of the saxagliptin add-on to insulin ± metformin trial. (A) Adjusted mean changes from baseline HbA1c level (LOCF) at week 52. (B) Adjusted mean changes from baseline FPG (LOCF) at week 52. (C) Proportions of patients achieving HbA1c level  7% (LOCF) at week 52. (D) Adjusted mean changes from baseline in body weight (LOCF) at week 52 in patients with CVD history versus no CVD history, with  2 and  1 CV risk factor, with and without hypertension, and with and without statin use.</p></td>
</tr>
<tr>
<td style='border-bottom: 2px solid grey; text-align: left;'><p class="">Abbreviations: CV, cardiovascular; CVD, cardiovascular disease; GLIP, glipizide; HbA1c, glycated hemoglobin; MET, metformin; SAXA, saxagliptin; SE, standard error.</p></td>
</tr>
</tbody>
</table>
